
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Stablepharma Begins Phase 1 Trial of Fridge-Free Tetanus-Diphtheria Vaccine
Details : SPVX02 is the lead candidate fridge-free tetanus and diphtheria vaccine, currently initiated phase 1 trials in United Kingdom.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $2.6 million
Deal Type : Funding
Stablepharma Secures €2.5M EIC Grant, Recognised Among Europe's Top 71 Innovators
Details : The grant comes as the company will move forward to accelerated the clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : SPVX02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $2.6 million
Deal Type : Funding
